Prevalence of epilepsy in Rochester, Minnesota: 1940-1980.
W A Hauser, J F Annegers, L T Kurland
https://pubmed.ncbi.nlm.nih.gov/1868801/Actively Recruiting
Led by Hospital Sirio-Libanes · Updated on 2024-03-26
312
Participants Needed
10
Research Sites
N/A
Total Duration
Researchers are studying biperiden as a potential preventive treatment for post traumatic epilepsy PTE, a common neurological complication after moderate or severe traumatic brain injury TBI. This research aims to evaluate if biperiden can reduce the occurrence of PTE, assess its side effects, and analyze its cost-effectiveness. The trial focuses on adult patients with moderate or severe TBI, as PTE often develops within two years after injury and currently lacks effective prevention. Participants are randomly assigned to receive either 5 mg of biperiden intravenously every 6 hours for 10 days or a placebo with similar administration. The treatment starts within 18 hours of brain injury. The study includes a two-year follow-up period with regular visits to monitor for epileptic seizures and other outcomes. The trial also examines brain activity through electroencephalogram analyses, genetic markers, and various neuropsychological functions. During the study, participants will undergo multiple assessments including EEG tests at set intervals, neuropsychological evaluations at 6 and 24 months, and quality of life questionnaires. Researchers will track seizure development, side effects of biperiden, and health status over two years. This long-term monitoring helps determine the drugs safety and effects on epilepsy prevention after brain injury.
CONDITIONS
Biperiden Trial for Epilepsy Prevention
E
Eliana Garzon, MD, PhD
M
Maira L Foresti, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Hospital Sirio-Libanes
Lead Sponsor
PROADI-SUS
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 10 days
Participants receive biperiden or placebo intravenously every 6 hours for 10 consecutive days after traumatic brain injury.
Daily visits for 10 days (in-person)
Duration - Up to 24 months
Participants are followed for up to 2 years to assess the development of epileptic seizures and other health outcomes.
Periodic visits at 1, 3, 6, 9, 12, 18, and 24 months (in-person)
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
W A Hauser, J F Annegers, L T Kurland
https://pubmed.ncbi.nlm.nih.gov/1868801/Sergio A Antoniuk
https://pubmed.ncbi.nlm.nih.gov/24072054/Maira Licia Foresti, Eliana Garzon, Carla Cristina Gomes Pinheiro...
https://pubmed.ncbi.nlm.nih.gov/36084082/Simone Bittencourt, Enéas Ferrazoli, Maria Fernanda Valente...
https://pubmed.ncbi.nlm.nih.gov/29096134/Raimondo D'Ambrosio, Emilio Perucca
https://pubmed.ncbi.nlm.nih.gov/15542983/Nicholas J DeVito, Ben Goldacre
https://pubmed.ncbi.nlm.nih.gov/30523135/Jeffrey Englander, Tamara Bushnik, Thao T Duong...
https://pubmed.ncbi.nlm.nih.gov/12638104/Simone Kastropil Benassi, Julieta Goncalves Silva Macedo Alves, Cristiane Gorgatti Guidoreni...
https://pubmed.ncbi.nlm.nih.gov/33714677/A M da Silva, A R Vaz, I Ribeiro...
https://pubmed.ncbi.nlm.nih.gov/2129092/Carlos Eduardo Romeu de Almeida, José Lopes de Sousa Filho, Jules Carlos Dourado...
https://pubmed.ncbi.nlm.nih.gov/26485419/Hospital Sirio-Libanes
Lead Sponsor
PROADI-SUS
Collaborating Sponsor